CRC Research Update

  • SCREENING

    FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults

    The FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 years and older who are at average risk, based on data from the PREEMPT CRC trial. (The ASCO Post)

  • RESEARCH

    Circulating Tumor DNA May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery

    Circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to overall survival findings from the phase II GALAXY study presented at ESMO GI Congress 2026. (The ASCO Post)

  • SCREENING

    Environmental Impact Study Compares Carbon Footprint of CRC Screening Tests

    A life cycle assessment at UCSF compared the environmental impacts of three CRC screening strategies—annual faecal immunochemical tests, CT colonographies every 5 years, or colonoscopies every 10 years—measuring global warming potential and damage to human health. (BMJ Public Health)

  • LIVING WITH CRC

    Most Patients Lack Documented Surveillance Plan After Polyp Removal

    A retrospective audit at King Saud University Medical City found that 74.9% of patients who underwent screening colonoscopy with polypectomy had no documented surveillance plan, and among those with a plan, only 14.0% overall were guideline-concordant. (J Taibah Univ Med Sci)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

These updates reflect ongoing efforts to improve screening access, refine surveillance practices, and personalize care based on molecular profiles.